Topical administration of TLR7 agonists, frequently utilized in animal models of psoriasis, initially triggers Th17-type inflammation; however, prolonged and continuous topical application leads to the production of autoantibodies29, wherein systemic inflammation may induce a breakdown of self-tolerance, particularly within the context of innate immune activation30. The gene discussed is TLR7; the disease is psoriasis.